1. Presented By Patrick Wen at 2014 ASCO Annual Meeting
A randomized, double‑blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients
Presented By Patrick Wen at 2014 ASCO Annual Meeting

2. Rationale for Immunotherapy in GBM
Presented By Patrick Wen at 2014 ASCO Annual Meeting

3. ICT-107 is an Autologous Six-antigen DC Vaccine
Presented By Patrick Wen at 2014 ASCO Annual Meeting

4. ICT-107 Phase I Highlights from ASCO 2013
Presented By Patrick Wen at 2014 ASCO Annual Meeting

5. Presented By Patrick Wen at 2014 ASCO Annual Meeting
ICT-107 Ph II Trial Design
Presented By Patrick Wen at 2014 ASCO Annual Meeting

6. Eligibility Criteria and Objectives
Presented By Patrick Wen at 2014 ASCO Annual Meeting

7. Presented By Patrick Wen at 2014 ASCO Annual Meeting
Patient Disposition<br />October 2013 and April 2014 Data Analysis
Presented By Patrick Wen at 2014 ASCO Annual Meeting

8. Presented By Patrick Wen at 2014 ASCO Annual Meeting
Patient Demographics
Presented By Patrick Wen at 2014 ASCO Annual Meeting

9. Safety – Common Adverse Events
Presented By Patrick Wen at 2014 ASCO Annual Meeting

10. Presented By Patrick Wen at 2014 ASCO Annual Meeting
Safety – SAEs Above Grade 3<br />Active Patients and Control Patients
Presented By Patrick Wen at 2014 ASCO Annual Meeting

11. Presented By Patrick Wen at 2014 ASCO Annual Meeting
OS (From Randomization) for ITT and PP Populations<br />Updated in April 2014
Presented By Patrick Wen at 2014 ASCO Annual Meeting

12. Presented By Patrick Wen at 2014 ASCO Annual Meeting
PFS for the ITT and PP Populations <br />(Central Radiology Review)<br />Updated in April 2014
Presented By Patrick Wen at 2014 ASCO Annual Meeting

13. Presented By Patrick Wen at 2014 ASCO Annual Meeting
MGMT Status Creates Two Different Patient Populations From the Survival Perspective<br />Per-Protocol Population with April 2014 Survival Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting

14. Presented By Patrick Wen at 2014 ASCO Annual Meeting
OS in the Unmethylated MGMT and HLA-A2† Subgroup<br />Per-Protocol Population with April 2014 Survival Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting

15. Presented By Patrick Wen at 2014 ASCO Annual Meeting
PFS in the Unmethylated MGMT and HLA-A2 Subgroup (Central Radiology Review)<br />Per-Protocol Population with April 2014 PFS Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting

16. Presented By Patrick Wen at 2014 ASCO Annual Meeting
OS in the Methylated MGMT and HLA-A2 Subgroup<br />Per-Protocol Population with April 2014 Survival Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting

17. Presented By Patrick Wen at 2014 ASCO Annual Meeting
PFS in the Methylated MGMT and HLA-A2 Subgroup<br />(Central Radiology Review)<br />Per-Protocol Population with April 2014 PFS Data
Presented By Patrick Wen at 2014 ASCO Annual Meeting

18. Quality of Life Assessed via FACT-BR and Performance Status
Presented By Patrick Wen at 2014 ASCO Annual Meeting

19. Proportion of Steroid Usage During Trial
Presented By Patrick Wen at 2014 ASCO Annual Meeting

20. Presented By Patrick Wen at 2014 ASCO Annual Meeting
Relationship between Indicators of Vaccine Potency and Survival<br />Cox Proportional Hazards Model – Assessments of DC Maturity and Activation in Vaccine Prior to Administration
Presented By Patrick Wen at 2014 ASCO Annual Meeting

21. Antigen-Specific Vaccine Response
Presented By Patrick Wen at 2014 ASCO Annual Meeting

22. Presented By Patrick Wen at 2014 ASCO Annual Meeting
Antigen Presentation in Primary Tumors<br />Percent of Patients Expressing Antigens via qPCR<br />
Presented By Patrick Wen at 2014 ASCO Annual Meeting

23. Conclusions for ICT-107 Ph II
Presented By Patrick Wen at 2014 ASCO Annual Meeting

24. Presented By Patrick Wen at 2014 ASCO Annual Meeting
Acknowledgements
Presented By Patrick Wen at 2014 ASCO Annual Meeting